Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United…
$14.27+1.21%
报价 2026-11-06
市值
$1.85B
EV
$2.19B
PE (TTM)
–
预期 PE
–
52 周区间距高点 -31.9%
$11.95$20.96
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| MESOMesoblast Limited | $1.85B | +1.2% | – | 78.3% | – | – | – | |
| ALMRAlamar Biosciences, Inc. | $1.95B | +4.3% | – | 58% | – | – | – | |
| VCYTVeracyte, Inc. | $1.94B | +0.7% | +14.3% | 72.1% | 33.7x | 27.8x | 23.4x | |
| HRMYHarmony Biosciences Holdings, Inc. | $1.93B | +2.0% | +17.2% | 77.2% | 10.0x | 4.3x | 5.5x | |
| MAZEMaze Therapeutics, Inc. | $1.9B | +5.1% | +545.2% | 95.3% | – | – | – | |
| SRPTSarepta Therapeutics, Inc. | $1.88B | +1.4% | -3.6% | 58.6% | – | – | – | |
| ZBIOZenas BioPharma, Inc. | $1.84B | +9.0% | -47.8% | 0% | – | – | – | |
| NVAXNovavax, Inc. | $1.78B | +10.2% | -61.5% | 77.3% | – | – | – | |
| AGIOAgios Pharmaceuticals, Inc. | $1.76B | +4.0% | +160.7% | 87.9% | – | – | – | |
| 同行中位数 | – | – | +14.3% | 74.6% | 21.9x | 16.1x | 14.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。